UK recognition strengthens Medclair’s position ahead of continued expansion within the NHS
UK recognition strengthens Medclair’s position ahead of continued expansion within the NHS
A recent article in the UK publication The Conversation highlights Newcastle Hospitals, where Medclair’s technology is being used to reduce the climate impact of nitrous oxide. The installation has also been evaluated in a clinical study published in the British Journal of Anaesthesia. With 155 obstetric units across NHS England, Medclair sees significant opportunities to expand its installed base and increase recurring revenue.
The article highlights how the healthcare sector can reduce the climate impact of nitrous oxide without restricting access to effective pain relief during childbirth. At the same time, the clinical study from Newcastle demonstrates significant environmental and occupational health benefits from Medclair's technology. Together, the practical application and the scientific results constitute an important reference for the company's continued expansion in the UK market.
"Newcastle is an important reference for us. Here we have both practical experience and scientific support for our technology. This strengthens our prospects of reaching more hospitals within the NHS. Every new installation contributes to a growing installed base that generates recurring revenue and creates opportunities for further business," says Jonas Lundh, CEO of Medclair.
Scientific study – British Journal of Anaesthesia (2026)
Utilising central and mobile destruction units during labour to reduce ambient nitrous oxide levels: a triple bottom line analysis, British Journal of Anaesthesia, 2026.
https://www.bjanaesthesia.org.uk/article/S0007-0912(26)00356-9/abstract
Article – The Conversation (2026)
https://theconversation.com/greener-maternity-care-starts-with-changing-hospitals-without-putting-pressure-on-pregnant-women-293497